Cognitive Decline in AD

Recruiting now

Conditions studied: Alzheimer Disease

In brief

There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors. In addition there may be biomarkers e.g. inflammatory cytokines that can contribute to cognitive decline. The impact of care arrangement and physical activity may also be important. Insulin signaling is impaired in Alzheimer disease (AD). We therefore propose to perform a cohort study of older people with AD. This will be based on an on-going AD registry which was designed to identify genetic biomarkers for AD. Detailed neurocognitive tests and lifestyle information are available. In addition, volumetric MRI brain scans were performed in all AD subjects. The hypothesis is that MRI brain volumes, serum biomarkers, physical activity, physical functioning are independently associated with cognitive decline in older people with AD. The objective is to identify risk factors of accelerated cognitive decline so that preventive measures can be designed to delay dependency in AD.

Key facts

Study ID

NCT03946930

Run by

Chinese University of Hong Kong

People needed

500

Starts

2018-12-13

Expected to finish

2027-12-31

Last updated by the study team

2024-08-21

Who can join

Age: 65 and older, up to 92. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Sufficient Cantonese competency for cognitive test
• Clinical diagnosis of AD
• FAST test staging 3-5

You may not qualify if…

• Subjects who refuse blood taking procedure
• No reliable family caregiver informant (person contact at least once a month)

Where it is running

• The Chinese University of Hong Kong — Hong Kong, Hong Kong (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.